Safety and efficacy of long-term nicotinamide mononucleotide supplementation on metabolism, sleep, and nicotinamide adenine dinucleotide biosynthesis in healthy, middle-aged Japanese men
Shintaro Yamaguchi,Junichiro Irie,Masanori Mitsuishi,Yuichi Uchino,Hideaki Nakaya,Ryo Takemura,Emi Inagaki,Shotaro Kosugi,Hideyuki Okano,Masato Yasui,Kazuo Tsubota,Kaori Hayashi,Jun Yoshino,Hiroshi Itoh
DOI: https://doi.org/10.1507/endocrj.ej23-0431
2024-01-01
Endocrine Journal
Abstract:Obesity and aging are major risk factors for several life-threatening diseases. Accumulating evidence from both rodents and humans suggests that the levels of nicotinamide adenine dinucleotide (NAD<sup>+</sup>), a regulator of many biological processes, declines in multiple organs and tissues with aging and obesity. Administration of an NAD<sup>+</sup> intermediate, nicotinamide mononucleotide (NMN), replenishes intracellular NAD<sup>+</sup> levels and mitigates aging- and obesity-associated derangements in animal models. In this human clinical study, we aimed to investigate the safety and effects of 8-week oral administration of NMN on biochemical, metabolic, ophthalmologic, and sleep quality parameters as well as on chronological alterations in NAD<sup>+</sup> content in peripheral tissues. An 8-week, single-center, single-arm, open-label clinical trial was conducted. Eleven healthy, middle-aged Japanese men received two 125-mg NMN capsules once daily before breakfast. The 8-week NMN supplementation regimen was well-tolerated; NAD<sup>+</sup> levels in peripheral blood mononuclear cells increased over the course of NMN administration. In participants with insulin oversecretion after oral glucose loading, NMN modestly attenuated postprandial hyperinsulinemia, a risk factor for coronary artery disease (n = 3). In conclusion, NMN overall safely and effectively boosted NAD<sup>+</sup> biosynthesis in healthy, middle-aged Japanese men, showing its potential for alleviating postprandial hyperinsulinemia.
endocrinology & metabolism